1/31/2012

Eli Lilly and Co. and Boehringer Ingelheim received FDA approval for Jentadueto, a type 2 diabetes medicine intended for use with exercise and diet. The oral treatment, which combines linagliptin and metformin hydrochloride, can be taken alone or with commonly prescribed sulfonylurea.

Related Summaries